Dianthus Therapeutics Conference Call Summary Company Overview - **Company**: Dianthus Therapeutics (NasdaqCM:DNTH) - **Date**: February 12, 2026 - **Key Executives**: Marino Garcia (CEO), Ryan Savitz (CFO) Key Industry and Company Insights 1. Transformational Year - 2025 was a pivotal year for Dianthus, marked by the first patient data in myasthenia gravis (MG), which exceeded expectations [2][60] 2. Product Pipeline - **DNTH212**: In-licensed from Leads Biolabs, a bifunctional fusion protein targeting BDCA2 to reduce type I interferon and BAFF/APRIL, showing potential as a best-in-class product [2][3] - **Clasiprubart**: An active C1s inhibitor with promising phase 2 data for MG, with two major catalysts expected in 2026 [3][4] 3. Upcoming Catalysts - **CIDP Phase 3 Study**: Interim responder analysis for the first 40 patients is anticipated in Q2 2026, accelerated from H2 2026 due to strong recruitment [4][16] - **MMN Phase 2 Results**: Expected in the second half of 2026 [4] 4. Competitive Landscape - **Riliprubart**: A competitor from Sanofi, currently in phase 3 studies for CIDP. Dianthus aims to demonstrate at least equal efficacy with a more convenient dosing regimen [10][12] - **Empaciperbart**: Another competitor in MMN, with Dianthus expecting similar efficacy but with advantages in administration and safety [31][39] 5. Efficacy Expectations - For CIDP, Dianthus aims for a responder rate of 40%-50% in the interim analysis, comparable to riliprubart's phase 2 data [12][17] - The company is focusing on a dosing regimen that is more efficient, potentially reducing the number of injections required [12][15] 6. Market Potential - The U.S. market for MG is estimated at $5 billion, with potential growth to $20-$25 billion as biologics penetrate further [60] - Dianthus anticipates capturing 5%-10% of the MG market, translating to $2-$4 billion in sales [60][62] 7. Financial Health - Dianthus ended the year with $514 million in cash, sufficient to fund operations through 2028 and support upcoming milestones [64] 8. Safety and Regulatory Considerations - Concerns about drug-induced lupus (DIL) were addressed, emphasizing the reliability of data from clinical trials versus anecdotal reports [54][56] - The company is confident in the safety profile of its products, with no reported cases of DIL in clinical programs [56] 9. Commercial Strategy - Dianthus plans to leverage the convenience of its auto-injector and the absence of a box warning to differentiate its products in the market [41][44] 10. Recruitment and Trial Design - The company is focusing on efficient recruitment strategies and trial designs that allow for quicker results and better patient outcomes [16][20] Conclusion Dianthus Therapeutics is positioned for significant growth with a strong pipeline and strategic focus on efficacy, safety, and market penetration. The upcoming data releases and competitive advantages in product administration are critical to its success in the evolving biotech landscape.

Dianthus Therapeutics (DNTH) Conference Summary Company Overview - **Company**: Dianthus Therapeutics - **Focus**: Development of DNTH103, a potent C1S inhibitor for treating severe autoimmune disorders, particularly in neuromuscular conditions [3][4] Key Points Product Development and Pipeline - **DNTH103**: A highly potent active C1S inhibitor designed for subcutaneous self-administration, similar to DUPIXENT, with a dosing schedule of every two weeks [4][13] - **Upcoming Data**: - Phase two data for Myasthenia Gravis (MG) expected in September 2025 [5] - Phase two study for Multifocal Motor Neuropathy (MMN) results anticipated in February 2026 [5] - Phase three interim responder analysis for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 2026 [5] Market Potential - **Target Conditions**: - Myasthenia Gravis (MG) - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Multifocal Motor Neuropathy (MMN) - **Patient Population**: Approximately 150,000 patients in the US across these three conditions, with significant unmet medical needs [6][7] Competitive Landscape - **Market Opportunity**: - MG is a multibillion-dollar market with potential for DNTH103 to become a first-line treatment [7] - CIDP data from competitors (e.g., Sanofi's rilipabart) indicates active C1S inhibition may outperform current standard treatments like IVIG [17][20] - **Comparative Efficacy**: - DNTH103 demonstrated superior potency in vitro compared to rilipabart, requiring lower doses for efficacy [22][23] - DNTH103's dosing is more patient-friendly, with a regimen of 300 mg every two weeks versus rilipabart's 600 mg weekly [21][23] Financial Position - **Balance Sheet**: Dianthus has a strong financial position with $332 million, providing a runway until the second half of 2027 to support ongoing clinical trials and product development [5] Safety and Efficacy Profile - **Safety Profile**: DNTH103 aims to avoid the safety issues associated with other complement inhibitors by selectively inhibiting the classical pathway without affecting the lectin and alternative pathways, reducing infection risks [16][27] - **Efficacy Goals**: The product aims to combine the efficacy of existing treatments while maintaining a favorable safety profile and convenient administration [10][14] Future Outlook - **Catalysts**: The upcoming data releases in 2025 and 2026 are expected to be significant catalysts for the company's stock and market position [5][30] - **Market Growth**: The MMN market is anticipated to grow, with DNTH103 positioned to capture a significant share due to its unique mechanism of action [24][28] Additional Insights - **Research and Development Strategy**: The company is focused on building a leading neuromuscular franchise by targeting three related diseases, leveraging clinical and commercial synergies [6] - **Regulatory Considerations**: The development strategy includes avoiding box warnings by maintaining a selective inhibition approach, which is crucial for market acceptance [16][26] This summary encapsulates the key points from the Dianthus Therapeutics conference, highlighting the company's strategic direction, product pipeline, market potential, and competitive advantages.